Bangalore: AstraZeneca Pharma India Ltd., has announced that it has received approval from Central Drugs Standard Control Organisation (CDSCO) in India for the import and marketing of Andexanet Alfa.
This ground-breaking treatment addresses life-threatening or refractory bleeding associated with the use of Factor Xa (FXa) inhibitors.
FXa inhibitors are increasingly employed for preventing and treating thrombotic events, such as deep vein thrombosis and pulmonary embolism, as well as in patients at high risk of stroke due to atrial fibrillation.
Read also: AstraZeneca Pharma India launches Centre of Excellence for severe asthma in Mumbai
While these medications effectively prevent unwanted clot formation, they also elevate the risk of major bleeding, which can be life-threatening, said Dr Sanjeev Panchal, Country President and Managing Director, AstraZeneca India.
Read also: AstraZeneca Voydeya approved in Japan for paroxysmal nocturnal haemoglobinuria
AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. AstraZeneca Pharma India Limited (AZPIL) is the operating company and covers manufacturing, sales and marketing activities of the company in India.
Read also: AstraZeneca Gets CDSCO Panel Nod to Study anti-cancer drug Dato-DXd and Durvalumab
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!